Table 1 Significantly altered pathways in gingivo-buccal oral squamous cell carcinoma.

From: Mutational landscape of gingivo-buccal oral squamous cell carcinoma reveals new recurrently-mutated genes and molecular subgroups

KEGG ID: description of pathways (No. of genes comprising pathway)

No. of patients in whom altered

Total no. of variants

P -value*

No. of genes with somatic SNV and indels

No. of genes amplified

No. of genes deleted

% of genes altered in pathway

hsa04115: p53 signalling pathway (n=68)

36

41

4.87 × 10−09

7

12

9

41.2

hsa04210: apoptosis (n=88)

37

49

5.21 × 10−09

13

16

8

42.0

hsa05203: viral carcinogenesis (n=207)

39

68

2.12 × 10−06

24

26

26

36.7

hsa04722: neurotrophin signalling pathway (n=120)

40

55

7.12 × 10−06

15

16

19

41.7

hsa04310: Wnt signalling pathway (n=151)

39

53

0.00095

21

16

20

37.7

hsa04151: PI3K–Akt signalling pathway (n=338)

46

104

0.00129

51

40

35

37.3

hsa04320: dorso-ventral axis formation (n=24)

15

18

0.0024

8

2

2

50.0

hsa04360: axon guidance (n=129)

28

51

0.00396

35

14

14

48.8

hsa04010: MAPK signalling pathway (n=259)

42

77

0.00706

35

37

31

39.8

hsa04510: focal adhesion (n=204)

33

74

0.02014

49

29

28

52.0

hsa04514: cell adhesion molecules (CAMs) (n=133)

19

34

0.02250

28

18

16

46.6

hsa04080: neuroactive ligand-receptor interaction (n=273)

30

55

0.02624

49

57

34

51.3

hsa04330: Notch signalling pathway (n=47)

17

20

0.04439

10

6

6

46.8

hsa04726: serotonergic synapse (n=113)

17

30

0.04671

18

21

12

45.1

  1. * P-values correspond to likelihood-ratio tests used to assess enrichment.